Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other incretin-based drugs are well-established treatments for type 2 diabetes mellitus (T2DM) and obesity due to their metabolic effects and favorable safety profiles [6]. Here, GLP1R is linked to type 2 diabetes mellitus.